Pipeline Updated February 21, 2025

Impacting the science of dermatology
through research.

ALTRENO® (tretinoin) Lotion, 0.05%

  • PRE-CLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA FILED
  • FDA
    APPROVAL
  • AVAILABLE
SEE CLINICAL TRIAL

ARAZLO® (tazarotene) Lotion, 0.045%

  • PRE-CLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA FILED
  • FDA
    APPROVAL
  • AVAILABLE
SEE CLINICAL TRIAL

BRYHALI® (halobetasol propionate) Lotion, 0.01%

  • PRE-CLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA FILED
  • FDA
    APPROVAL
  • AVAILABLE
SEE CLINICAL TRIAL

CABTREO® (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1%

  • PRE-CLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA FILED
  • FDA
    APPROVAL
  • AVAILABLE
SEE CLINICAL TRIAL

DUOBRII® (halobetasol propionate and tazorotene) Lotion, 0.01%/0.045%

  • PRE-CLINICAL
  • PHASE I
  • PHASE II
  • PHASE III
  • NDA FILED
  • FDA
    APPROVAL
  • AVAILABLE
SEE CLINICAL TRIAL

Science-backed products

We're passionate about offering a wide range of FDA-approved treatments for a variety of dermatological conditions.

our products